Recent proof-of-principle experiments by Joslin Diabetes Center and Massachusetts General Hospital (MGH) researchers, however, offer hope that physicians may one day be able to identify individuals with preclinical type 1 diabetes, and to assess the effectiveness of therapies much earlier than is now possible. Findings of the study will be published in the September issue of the Journal of Clinical Investigation.
Type 1 diabetes is an autoimmune disease in which the body's immune system mistakenly attacks its own insulin-producing beta cells and eventually kills them. Early in this process, white blood cells called T lymphocytes infiltrate the islets of the pancreas (an inflammatory condition known as insulitis), causing the blood vessels to become leaky. Over time, this infiltration of lymphocytes destroys the beta cells, leading to high blood glucose and full-blown diabetes. Today, the only accurate method for detecting the progression or regression of insulitis is a biopsy of the pancreas, which is almost never performed because it is an invasive and potentially risky procedure.
"The most exciting aspect of this study is that it demonstrates that we can, at least in mice, use a non-invasive imaging method to predict at a very early time whether a drug will stop the progression of diabetes or not. In fact, the drug we used in these proof-of-principle experiments is analogous to one currently being tried in humans with diabetes, and so far showing great promise," said Diane Mat
'"/>
Source:Joslin Diabetes Center